Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

UK BIA Antibody Taskforce reaches major milestone against COVID-19

The UK Antibody Taskforce, led by Alchemab’s CSO, Dr Jane Osbourn OBE, has identified antibody combinations for a potential therapeutic antibody cocktail to treat COVID-19.

Base Genomics acquired by Exact Sciences for $410M

The OSI backed venture and BioEscalator resident, Base Genomics has been acquired by the US based molecular diagnostics company, Exact Sciences for $410m

Alchemab announced as finalists for OBN Awards 2020

Novel therapeutics company, Alchemab Therapeutics, has been shortlisted in the Best Start-Up category of the 12th Annual OBN Awards.

Alchemab collaborate with leading AI institute to advance drug discovery

BioEscalator residents Alchemab Therapeutics announce partnership the Alberta Machine Intelligence Institute (Amii), a global leader in machine intelligence.

Oncology expert Carsten Reinhardt joins Theolytics Board of Directors

Immatics Chief Development Officer, Dr Carsten Reinhardt joins the board to boost global development of Theolytics oncolytic viral technology

BioEscalator joins forces with BioCity and Oxford AHSN to support early-stage medical start-ups

Last week the BioEscalator worked with Nottingham’s BioCity and the Oxford Academic Health Science Network to provide a series of sold-out commercialisation workshops for the entrepreneurial community in Oxfordshire and beyond.

Agile start-ups partner with academics to find COVID-19 solutions

Three companies at Oxford’s BioEscalator are developing new detection methods and have discovered potential therapeutics in the fight against COVID-19.

MiroBio graduates from the BioEscalator

Rapidly growing immune cell regulation company relocates to The Oxford Science Park

Ervaxx rebrands as Enara Bio

Enara Bio will have a broader emphasis on the discovery and development of novel TCR-based cancer immunotherapies

Theolytics announced winners of the Santander Pitch Finale

Following a fantastic event, Theolytics was announced the winner of the BioEscalator’s inaugural Pitch Finale, which was kindly supported by Santander Universities UK.

Base Genomics raise $11M

Epigenetics company Base Genomics has launched with a team of leading scientists and clinicians to set a new gold standard in DNA methylation detection.

Upcoming - Santander Pitch Finale

This Friday's Pitch finale will see pitches from our top 3 start-ups; Alchemab, Bioarchitech and Theolytics.

Pitch Battle @BioEscalator

MiroBio won the BioEscalator’s inaugural Pitch Battle contest held digitally at the pizza social on 17 April 2020.

MoA Technology Secures Series A Funding

MoA Technology secures £6.3m ($8m) of funding

MiroBio Launch

MiroBio launches with £27m ($34m) Series A from leading life sciences investors.

Theolytics Limited comes out of stealth mode

Virology spinout Theolytics emerges from stealth with £2.5m seed and Dr Ken Powell as chair.

BioEscalator Launch

Baroness Nicola Blackwood of North Oxford, Parliamentary Under Secretary of State for Innovation, has officially opened the Oxford BioEscalator.

PepGen Innovate UK Grant

PepGen awarded significant Innovate UK Grant